Pediatric Clinics of North America - CIPERJ

VON WILLEBRAND DISEASE
391
[24] Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with
a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325–31.
[25] Favaloro EJ. The utility of the PFA-100 in the identification of von Willebrand disease:
a concise review. Semin Thromb Hemost 2006;32:537–45.
[26] Howard MA, Firkin BG. Ristocetinda new tool in the investigation of platelet aggregation.
Thromb Diath Haemorrh 1971;26:362–9.
[27] Cooney KA, Lyons SE, Ginsburg D. Functional analysis of a type IIB von Willebrand
disease missense mutation: increased binding of large von Willebrand factor multimers to
platelets. Proc Natl Acad Sci U S A 1992;89:2869–72.
[28] Hoyer LW, Rizza CR, Tuddenham EGD, et al. Von Willebrand factor multimer patterns in
von Willebrand’s disease. Br J Haematol 1983;55:493–507.
[29] Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of
von Willebrand disease. Blood 1987;69:1691–5.
[30] Casonato A, Pontara E, Bertomoro A, et al. Fainting induces an acute increase in the
concentration of plasma factor VIII and von Willebrand factor. Haematologica 2003;88:
688–93.
[31] Stakiw J, Bowman M, Hegadorn C, et al. The effect of exercise on von Willebrand factor and
ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease. J Thromb
Haemost 2008;6:90–6.
[32] Kadir RA, Chi C. Women and von Willebrand disease: controversies in diagnosis and
management. Semin Thromb Hemost 2006;32:605–15.
[33] Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during
childhood. Blood 1992;80:1998–2005.
[34] Sosothikul D, Seksarn P, Lusher JM. Pediatric reference values for molecular markers in
hemostasis. J Pediatr Hematol Oncol 2007;29:19–22.
[35] Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification
of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
J Thromb Haemost 2006;4:2103–14.
[36] Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003;101:
2089–93.
[37] James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand
disease: results from a Canadian cohort study. Blood 2007;109:145–54.
[38] Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of
families historically diagnosed with type 1 von Willebrand disease in the European study,
molecular and clinical markers for the diagnosis and management of Type 1 von Willebrand
disease (MCMDM-1VWD). Blood 2007;109:112–21.
[39] O’Brien LA, James PD, Othman M, et al. Founder von Willebrand factor haplotype associated
with type 1 von Willebrand disease. Blood 2003;102:549–57.
[40] Lyons SE, Bruck ME, Bowie EJW, et al. Impaired intracellular transport produced by
a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992;267:4424–30.
[41] Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and
factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J
Med 1980;302:1047–51.
[42] Miller JL, Castella A. Platelet-type von Willebrand’s disease: characterization of a new
bleeding disorder. Blood 1982;60:790–4.
[43] Brychaert MC, Pietu G, Ruan C, et al. Abnormality of glycoprotein Ib in two cases of
‘‘pseudo’’ von Willebrand’s disease. J Lab Clin Med 1985;106:393–400.
[44] Mancuso DJ, Kroner PA, Christopherson PA, et al. Type 2M:Milwaukee-1 von Willebrand
disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand
factor A1 domain causes deficient binding of von Willebrand factor to platelets. Blood
1996;88:2559–68.
[45] Mazurier C. von Willebrand disease masquerading as haemophilia A. Thromb Haemost
1992;67:391–6.